Free Trial
OTCMKTS:CLPBY

Coloplast A/S Q2 2026 Earnings Results & Report

Coloplast A/S logo
$7.04 +0.16 (+2.33%)
As of 03:57 PM Eastern

Coloplast A/S beat analyst earnings expectations but missed on revenue in its Q2 2026 results, released May 12, 2026. The company reported EPS of $0.10 versus the $0.09 consensus estimate, while revenue of $1.11 billion fell short of the $1.11 billion estimate by $0.92 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

Coloplast A/S EPS Results

Actual EPS
$0.10
Consensus EPS
$0.09
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Coloplast A/S Revenue Results

Actual Revenue
$1.11 billion
Expected Revenue
$1.11 billion
Beat/Miss
Missed by -$918.00 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Coloplast A/S' next earnings date is estimated for Tuesday, November 3, 2026, based on past reporting schedules.

Conference Call Resources

Coloplast A/S Q2 2026 Earnings FAQ

Coloplast A/S (OTCMKTS:CLPBY) reported earnings of $0.10 per share for Q2 2026, beating the consensus estimate of $0.09. The report was announced on Tuesday, May 12, 2026.

Coloplast A/S reported revenue of $1.11 billion for Q2 2026, against a consensus estimate of $1.11 billion.

Coloplast A/S' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Coloplast A/S on the company's earnings history page.

Coloplast A/S Earnings Headlines

Coloplast A/S (OTCMKTS:CLPBY) Stock Price Up 3.9% - Should You Buy?
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
CLPBY Share News Today
Coloplast: Went 'BUY' A Bit Early
See More Coloplast A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coloplast A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coloplast A/S and other key companies, straight to your email.

About Coloplast A/S

Coloplast A/S (OTCMKTS:CLPBY) is a Denmark-based medical technology company that develops and markets products and services for people with intimate and chronic healthcare needs. Its principal business areas include ostomy care, continence care, wound and skin care, and interventional urology.

The company’s product portfolio includes ostomy bags and accessories, skin-protection products, intermittent catheters, bowel-management systems, and devices used in urological procedures. Recognized brands include SenSura and Brava in ostomy care, SpeediCath in continence care, and Peristeen for bowel management.

Coloplast traces its origins to the 1950s, when nurse Elise Sørensen developed an adhesive ostomy bag to help her sister manage an ileostomy. The company was established in 1957 by Aage Louis-Hansen and his wife, Johanne Louis-Hansen. Headquartered in Humlebæk, Denmark, Coloplast serves healthcare professionals and patients in markets across Europe, North America, and other international regions. Kristian Villumsen has served as the company’s president and chief executive officer.

View Coloplast A/S Profile